These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3896456)

  • 1. Harnessing T-lymphocytes for human cancer immunotherapy.
    Hirshaut Y; Slovin SF
    Cancer; 1985 Sep; 56(6):1366-73. PubMed ID: 3896456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo.
    Crossland KD; Lee VK; Chen W; Riddell SR; Greenberg PD; Cheever MA
    J Immunol; 1991 Jun; 146(12):4414-20. PubMed ID: 1674958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
    Shu SY; Chou T; Rosenberg SA
    J Immunol; 1987 Jul; 139(1):295-304. PubMed ID: 2953816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive immunotherapy of cancer with immune and activated lymphocytes: experimental and clinical studies.
    Parmiani G; Sensi ML; Balsari A; Colombo MP; Gambacorti-Passerini C; Grazioli L; Rodolfo M; Cascinelli N; Fossati G
    Ric Clin Lab; 1986; 16(1):1-20. PubMed ID: 2874605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice.
    Shu S; Chou T; Rosenberg SA
    Cancer Res; 1987 Mar; 47(5):1354-60. PubMed ID: 3102046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy.
    Oelke M; Moehrle U; Chen JL; Behringer D; Cerundolo V; Lindemann A; Mackensen A
    Clin Cancer Res; 2000 May; 6(5):1997-2005. PubMed ID: 10815925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer immunotherapy by local transfer of autologous T lymphocytes cultured with T cell growth factor and autologous tumor extract: a clinical trial.
    Kan N; Ohgaki K; Yamasaki N; Hori T; Nakayama N; Nio Y; Inamoto T; Hikasa Y
    Nihon Geka Hokan; 1983 Nov; 52(6):841-53. PubMed ID: 6380446
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
    Rosenberg SA
    J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy of murine and human tumors in mice with lymphokines and interleukin-2-propagated lymphocytes.
    Kedar E; Chriqui-Zeira E; Kyriazis AP
    J Biol Response Mod; 1984 Oct; 3(5):517-26. PubMed ID: 6334139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of long-term cell lines and lymphoid clones reactive against murine and human tumors: a new approach to the adoptive immunotherapy of cancer.
    Rosenberg SA; Eberlein TJ; Grimm EA; Lotze MT; Mazumder A; Rosenstein M
    Surgery; 1982 Aug; 92(2):328-36. PubMed ID: 6980492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo effects of lymphocytes sensitized in vitro against tumor cells.
    Treves AJ; Cohen IR; Schechter B; Feldman M
    Ann N Y Acad Sci; 1976; 276():165-75. PubMed ID: 1088382
    [No Abstract]   [Full Text] [Related]  

  • 13. Potential for specific cancer therapy with immune T lymphocytes.
    Cheever MA; Greenberg PD; Fefer A
    J Biol Response Mod; 1984; 3(2):113-27. PubMed ID: 6233396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour inhibition by interleukin-2 at the tumour/host interface.
    Forni G; Giovarelli M; Santoni A; Modesti A; Forni M
    Biochim Biophys Acta; 1986 Dec; 865(3):307-27. PubMed ID: 3539200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression.
    Nakajima F; Khanna A; Xu G; Lagman M; Haschemeyer R; Mouradian J; Wang JC; Stenzel KH; Rubin AL; Suthanthiran M
    Proc Natl Acad Sci U S A; 1994 Aug; 91(17):7889-93. PubMed ID: 8058730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive immunotherapy of cancer: accomplishments and prospects.
    Rosenberg SA
    Cancer Treat Rep; 1984 Jan; 68(1):233-55. PubMed ID: 6362866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific chemoimmunotherapy in tumor-bearing mice with extracted antigen, cyclophosphamide, and intrasplenic administration of interleukin-2.
    Kahan BD; Nomi S; Pellis NR
    Cancer; 1986 Feb; 57(3):477-83. PubMed ID: 3484658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take.
    Kruse CA; Lillehei KO; Mitchell DH; Kleinschmidt-DeMasters B; Bellgrau D
    Proc Natl Acad Sci U S A; 1990 Dec; 87(24):9577-81. PubMed ID: 2263613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific cytotoxicity of a long-term cultured T-cell clone on human autologous mammary cancer cells.
    Sato T; Sato N; Takahashi S; Koshiba H; Kikuchi K
    Cancer Res; 1986 Sep; 46(9):4384-9. PubMed ID: 3488124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms.
    Melief CJ; Kast WM
    Semin Cancer Biol; 1991 Oct; 2(5):347-54. PubMed ID: 1773050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.